Histocell closes a $$2.5M round
The Basque biopharmaceutical company Histocell, a specialist in regenerative medicine and cell therapy, has closed a round of capital increase 2.5 million for the launch of its healing product on the international market at the end of 2015. Reoxcare.
This is the first of the financing rounds that Histocell plans to carry out in its 2015-2020 strategic plan, but the investment needs reach four million euros, which will be used primarily to complete the development of three medical devices and finalise the clinical phases of two cellular medicines.
Histocell's main shareholders have participated in the round, including Orza AIE, investment vehicle of ElkarkidetzaGestión de Capital Riesgo del País Vasco and the Group IMQHe has also joined Seed Capital Bizkaia as a new BI partner.
For the time being, the company has already reached agreements for the marketing of Reoxcare in different European and Asian markets, such as the one signed with the company Luqa Pharma for China, Hong Kong and Macao.
Biotica closes financing round
The technology-based company Biótica, has closed a round that has been attended by Caixa Capital Riscthrough the Caixa Capital Micro II fund, the ComVal Emprende fund, managed by Clave Mayor and previous shareholders such as the promoter partners Adrián Fortuño, Guillermo Rodríguez and Iproma (Gimeno Group).
The funds raised will enable Biotica to boost the commercial launch of its online legionella detection system, Legiolab.
The technology company, located in the Science, Technology and Business Park of the Jaume I University of Castellón, is dedicated to the development and commercialisation of systems for the rapid detection of pathogenic microorganisms. It currently has several products in the commercialisation phase, such as the test LEGIPID and CLEANPID, both of which are marketed internationally.
Biotechnology scenario in Spain
Cristina Garmendia, president of the Fundación Cotec for Technological Innovation and former Minister for Science and Innovation; Regina Revilla, President of the Asociación Española de Bioempresas (Asebio)and Andrés Ballesteros, CEO and founder of the company Vivia Biotech talkedat the third debate on theCyT en 60 minutoson the past, present and future of biotechnology.
Among the main conclusions reached, we can highlight that the 21st century is the century of biotechnology in Spain, with a prodigious first decade, with more than 500 companies having been created in the last 15 years, a figure that places Spain, as Revilla confirmed, "as one of the countries that has created the most biotech companies this century".
In addition, international venture capital looks very favourably on the Spanish biotech sector, something that was not the case years ago. The three speakers agreed that the financial environment needs to be developed more and better so that venture capital enters Spain, settles in, and can leave easily when its presence in business development is no longer necessary.
If you are looking for financing, both public and private, please contact us on +34. 946424142. Abra-Invest has a team with extensive experience in both fields.
Other posts that may interest you
Biotech investment news: Era Biotech, Aura Bioscience, Quirumed and others (March 2015)
Operations Biotechnology February 2015